Russell Investments Group, Ltd. Zymeworks Inc. Transaction History

Russell Investments Group, Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 04, 2022	SELL	$4.65 - $7.43 $447,037 - $714,297	-96,137 Reduced 64.14%	53,755 $330,000
Q1 2022 May 05, 2022	BUY	$6.0 - $16.98 $211,584 - $598,782	35,264 Added 30.76%	149,892 $980,000
Q4 2021 Jan 21, 2022	BUY	$15.19 - $29.33 $146,796 - $283,445	9,664 Added 9.21%	114,628 $1.88 Million
Q3 2021 Nov 08, 2021	BUY	$27.35 - $37.28 $553,017 - $753,801	20,220 Added 23.86%	104,964 $3.05 Million
Q2 2021 Aug 04, 2021	BUY	$26.5 - $38.23 $2.17 Million - $3.14 Million	82,039 Added 3032.87%	84,744 $2.94 Million
Q1 2021 May 10, 2021	SELL	$29.83 - $56.81 $178,830 - $340,575	-5,995 Reduced 68.91%	2,705 $85,000
Q4 2020 Feb 08, 2021	BUY	$39.12 - $54.99 $340,344 - $478,413	8,700 New	8,700 $411,000
Q3 2020 Nov 09, 2020	SELL	$29.21 - $46.58 $103,753 - $165,452	-3,552 Closed	0 $0
Q2 2020 Aug 05, 2020	BUY	$33.67 - $40.0 $101,010 - $120,000	3,000 Added 543.48%	3,552 $128,000
Q1 2020 May 06, 2020	BUY	$24.28 - $49.8 $13,402 - $27,489	552 New	552 $19,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $895M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.